- Home
- Products
Krazati (Adagrasib)
Krazati (Adagrasib)
- Medicine Name: Krazati
- Generic Name: Adagrasib
- Dosage Form & Strength: Tablets – 200 mg
- Manufactured By: Mirati Therapeutics, Inc.
Indications and Usage: Krazati is an innovative KRAS G12C inhibitor developed to support adult patients diagnosed with locally advanced or metastatic non-small cell lung cancer (NSCLC) carrying the KRAS G12C mutation. It is intended for those who have undergone at least one prior systemic treatment, as determined by an FDA-approved test.
This medication has received accelerated FDA approval based on overall response rate (ORR) and duration of response (DOR). Ongoing trials will further validate its clinical benefits.
Dosage and Administration:
- Recommended Dose: 600 mg orally twice daily.
- Tablets should be swallowed whole, with or without food.
Contraindications:
- None
- Gastrointestinal Effects: Monitor for symptoms like nausea, diarrhea, or vomiting. Provide supportive care and adjust dosage as needed.
- QTc Interval Prolongation: Avoid co-administration with QT-prolonging drugs. Monitor ECG and electrolytes regularly, especially in at-risk patients.
- Hepatotoxicity: Conduct liver function tests before initiating treatment and monthly for at least three months or as clinically indicated. Modify or discontinue dosage based on test results.
- Interstitial Lung Disease / Pneumonitis: Assess for new or worsening respiratory symptoms. Suspend treatment if suspected and discontinue permanently if ILD is confirmed.
Adverse Reactions:
- Common side effects (≥ 25%): Nausea, vomiting, diarrhea, fatigue, appetite loss, dyspnea, musculoskeletal pain, renal impairment, edema, and hepatotoxicity.
- Common Grade 3 or 4 lab abnormalities (≥ 2%): Low lymphocytes, low hemoglobin, high ALT/AST, low potassium/sodium, increased lipase, reduced neutrophils, and elevated alkaline phosphatase.
Drug Interactions: Avoid concurrent use with:
- Strong CYP3A4 inducers/inhibitors
- Sensitive substrates of CYP3A4, CYP2C9, CYP2D6
- P-gp substrates
- QT-prolonging agents Refer to the prescribing information for comprehensive interaction guidance.
Required Documents for Import:
- A valid prescription from a qualified medical practitioner
- Diagnostic reports
- Government-issued photo ID of the patient
Order Confirmation:
- Receipt of valid prescription
- Import permit if required
Availability in India: Krazati (Adagrasib) tablets are available in India through Global Rare Meds under the Named Patient Supply (NPS) program. We support compliant and transparent sourcing of Krazati from certified suppliers across the USA, Canada, Europe, and Australia.
Krazati is available for patients, hospitals, and physicians in cities including Mumbai, Delhi, Chennai, Kolkata, Hyderabad, Bangalore, Pune, Ahmedabad, Lucknow, Jaipur, Chandigarh, and more.
To enquire:
- Phone/WhatsApp: +91-99675 15602
- Email: info@globalraremeds.com
Global Rare Meds provides trusted global access to Krazati through a secure and transparent sourcing model. All prescriptions are validated by licensed pharmacists and dispatched directly to the patient’s address from our Ambernath, Thane District fulfillment center.
We ensure the safe and timely delivery of Krazati to both domestic and international locations.
What is Krazati used for?
Krazati is prescribed to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC) in adults with prior systemic therapy.
How does Krazati work?
Krazati targets and inhibits the KRAS G12C mutation, helping to stop or slow down the growth of cancer cells.
Who is eligible for Krazati?
Adults with confirmed KRAS G12C-mutated NSCLC via an FDA-approved test and who’ve undergone prior treatment.
What are the common side effects?
Nausea, vomiting, diarrhea, fatigue, and liver-related issues are among the common side effects.
Is Krazati available in India?
Yes, it is available through Global Rare Meds with a valid doctor’s prescription and required documentation.
Is Krazati FDA approved?
Yes, Krazati received FDA approval in 2022.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
